Brits suffering from back pain could be entitled to extra cash from the Department for Work and Pensions (DWP). They are ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...

Ascendis Pharma secured Food and Drug Administration approval under the agency's accelerated approval program for Yuviwel, a treatment for the genetic condition that causes dwarfism.

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing ...

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.

Researchers from The University of Osaka have developed a mouse model for achondroplasia. The model identified the importance ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to narrowing of the skeletal structures surrounding the spinal cord.

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to narrowing of the ...

BridgeBio expects to become a cash-generation engine by 2028, projecting over $600,000,000 in profit from its four post-Phase 3 assets. Cash burn is projected to hold steady through 2026 as rising ...

BioMarin Pharmaceutical BMRN reported fourth-quarter 2025 adjusted earnings per share of 46 cents, beating the Zacks Consensus Estimate of 25 cents. However, earnings declined 50% year over year ...

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...